EGFR and non-small cell lung carcinoma: The results of several observational (non-interventional) studies of NSCLC treatment patterns conducted in recent years leading up to 2013 indicate that testing for EGFR mutation is increasing over time in conjunction with increased prescribing of EGFR TKIs [25–31].